Evidence map›Paper›PMID 30014222›Full record

ArticleCancer chemotherapy and pharmacology2018

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Amita Patnaik, Michael Gordon, Frank Tsai, Kyriakos P Papadopoulos, Drew Rasco, Muralidhar Beeram, Siqing Fu, Filip Janku, Scott M Hynes, Sushma R Gundala and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Amita PatnaikSouth Texas Accelerated Research Therapeutics (START), 4383 Medical Drive, Suite 4026, San Antonio, TX, USA. Amita.Patnaik@startsa.com.
Michael GordonHonorHealth Research Institute, Scottsdale, AZ, USA.
Frank TsaiHonorHealth Research Institute, Scottsdale, AZ, USA.
Kyriakos P PapadopoulosSouth Texas Accelerated Research Therapeutics (START), 4383 Medical Drive, Suite 4026, San Antonio, TX, USA.ORCID 0000-0002-0667-2620
Drew RascoSouth Texas Accelerated Research Therapeutics (START), 4383 Medical Drive, Suite 4026, San Antonio, TX, USA.
Muralidhar BeeramSouth Texas Accelerated Research Therapeutics (START), 4383 Medical Drive, Suite 4026, San Antonio, TX, USA.
Siqing FuCancer Medicine Division, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
Filip JankuCancer Medicine Division, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.ORCID 0000-0002-8123-4065
Scott M HynesEli Lilly and Company, Indianapolis, IN, USA.
Sushma R GundalaEli Lilly and Company, Indianapolis, IN, USA.ORCID 0000-0001-6545-7763
Melinda D WillardEli Lilly and Company, Indianapolis, IN, USA.
Wei ZhangEli Lilly and Company, Indianapolis, IN, USA.
Aimee Bence LinEli Lilly and Company, Indianapolis, IN, USA.
David HongCancer Medicine Division, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.ORCID 0000-0001-8721-1609

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The original version of this article unfortunately contained a mistake. The co-authors' names were incorrect.

Identifiers

PMID30014222
PMCPMC6829701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.